Oxford Nanopore Technologies

Oxford Nanopore Technologies Limited, also known as the MinION technology, is a U.K.-based company which is developing and selling nanopore sequencing products for the direct, electronic analysis of single molecules.

History

The company was founded in 2005 as a spin-out from the University of Oxford by Hagan Bayley, Gordon Sanghera, and Spike Willcocks, with seed funding from the IP Group.[6][7] As of 2014 the company had raised over £250 million in investment.

Executive – Dr Gordon Sanghera

Gordon Sanghera was co-founder of Oxford Nanopore, together with Hagan Bayley and IP Group. He was appointed CEO in June 2005. He brings over 20 years’ experience in the design, development and global launch of disruptive platform sensor technologies.

Dr Sanghera’s PhD in bioelectronics sensing was followed by a career at MediSense an Oxford spin-out that delivered a new generation glucose technology to the market.  Following the acquisition of MediSense by Abbott Laboratories  Dr Sanghera held both UK and US VP and Director-level positions, including VP World Wide Marketing, Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose bio-electronic systems for the consumer and hospital medical markets. He has also developed and validated production processes to meet with the regulatory requirements for USA and Europe.

Gordon has a PhD in bio-electronic technology and a degree in Chemistry.